Viralgen Vector Core

Cesar Trigueros, Chief Scientific Officer

Oct. 12 | 10:15am | Ecolab Life Sciences Ballroom 

San Sebastian, Spain


Viralgen is an independently operated Contract Development and Manufacturing Organization (CDMO), founded in 2017 as a joint venture between AskBio and Columbus Venture Partners (a venture capital firm based in Spain). As leading manufacturers of cGMP-certified AAV, Viralgen uses the Pro10TM based suspension manufacturing platform, a technology licensed from AskBio and developed by co-founder R. Jude Samulski, PhD, at University of North Carolina. It is believed that Pro10™ increases scalability, performance and precision of AAV therapies. Located in Spain, in the Gipuzkoa Science and Technology Park, Viralgen produces AAV gene therapy treatments for pharmaceutical and biotech companies with the aim of accelerating the delivery of new treatments that can improve patients’ lives. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions